Aerovate Therapeutics Files Routine 8-K on Jan 8, 2024

Ticker: JBIO · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1798749

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, compliance

TL;DR

**Aerovate filed a standard 8-K, no major news, just regulatory upkeep.**

AI Summary

Aerovate Therapeutics, Inc. filed an 8-K on January 8, 2024, to disclose information under Regulation FD and provide financial statements and exhibits. This filing, while routine, confirms the company's ongoing compliance with SEC reporting requirements and its listing on The Nasdaq Global Market under the ticker AVTE. For investors, this matters because it signals business as usual for Aerovate, a pharmaceutical preparations company, without any immediate red flags or significant new developments, reinforcing stability in its operational transparency.

Why It Matters

This filing indicates Aerovate Therapeutics is maintaining its regulatory compliance, which is a basic expectation for publicly traded companies. It doesn't contain new material information but confirms ongoing transparency.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material information that would introduce significant risk.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate new developments for Aerovate Therapeutics. It's a non-event that confirms the company's operational status and regulatory adherence, suggesting no need for immediate action based solely on this 8-K.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of Aerovate Therapeutics, Inc.'s 8-K filing dated January 8, 2024?

The primary purpose of Aerovate Therapeutics, Inc.'s 8-K filing on January 8, 2024, is to disclose information under Regulation FD and to provide financial statements and exhibits, as indicated by the 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits' sections.

On which stock exchange is Aerovate Therapeutics, Inc.'s Common Stock registered?

Aerovate Therapeutics, Inc.'s Common Stock, with a $0.0001 par value per share, is registered on The Nasdaq Global Market, as stated under 'Name of each exchange on which registered'.

What is the ticker symbol for Aerovate Therapeutics, Inc.?

The trade symbol for Aerovate Therapeutics, Inc.'s Common Stock is AVTE, as listed under 'Trade Symbol(s)'.

What is the state of incorporation for Aerovate Therapeutics, Inc.?

Aerovate Therapeutics, Inc. is incorporated in Delaware, as indicated by 'State or other jurisdiction of incorporation: Delaware'.

What is the business address and phone number of Aerovate Therapeutics, Inc. as per the filing?

The business address for Aerovate Therapeutics, Inc. is 930 Winter Street, Suite M-500, Waltham, Massachusetts 02451, and their business phone number is (617) 443-2400, according to the 'BUSINESS ADDRESS' and 'BUSINESS PHONE' sections.

Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-08 07:59:17

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. Aerovate Therapeutics, Inc. (the "Company") is furnishing a corporate presentation, attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company intends to use from time to time in meetings with investors and others beginning on January 8, 2024. The corporate presentation will also be available in the "Events & Presentations" section of the Company's website at https://ir.AerovateTx.com/events-presentations. The information under this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Corporate presentation of Aerovate Therapeutics, Inc., furnished herewith . 104 Cover Page Interactive Data File SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aerovate Therapeutics, Inc. Date: January 8, 2024 By: /s/ Timothy P. Noyes Timothy P Noyes Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing